The objective of this study is to observe the safety of paricalcitol utilization in pediatric

patients being treated for secondary hyperparathyroidism (SHPT). Patients will be

followed for a minimum of 3 months and up to approximately 36 months to monitor the

incidence of hypercalcemia. The safety will be primarily measured by the proportion of

patients developing at least one episode of hypercalcemia (calcium > 10.2 mg/dL). We

will also measure incident rates of adverse events and serious adverse events, and the

change from baseline in laboratory assessments, height and weight